health
This new GLP-1 play is on a tear. UBS sees nearly a 50% gain from here
MBX Biosciences has rallied more than 230% over the past year, but there's room for still more upside from current levels, according to UBS.
TL;DR
- UBS maintains a buy rating on MBX Biosciences with a $60 price target, suggesting nearly 50% potential upside.
- Positive data from MBX's GLP-1 and GIPR obesity study shows early proof of concept, competitive efficacy, and improved tolerability.
- MBX Biosciences' shares have increased by over 230% in the past year, driven by the exploding market for weight-management drugs.
- The market for type-2 diabetes and obesity treatments generated $79 billion in sales in 2025 and is expected to reach $190 billion by 2035.
- MBX Biosciences' GLP-1 demonstrated slightly higher efficacy than tirzepatide (active ingredient in Eli Lilly's Zepbound) at four weeks and appears to be well-tolerated.
- The consensus on Wall Street is bullish, with 10 out of 11 analysts rating MBX as a buy or strong buy.